Nivolumab with docetaxel for advanced castration-resistant prostate cancer

Nivolumab in addition to docetaxel is in clinical development for the treatment of adult males with advanced, castration-resistant prostate cancer. Prostate cancer is a common cancer caused by the growth of a tumour on the prostate gland. Advanced prostate cancer is a form of prostate cancer where the tumours have spread to other areas of the body. Castration-resistant prostate cancer refers to tumours that are still able to grow despite the levels of testosterone in the body being very low. The aim of treatment for advanced prostate cancer is to control the progression of the cancer, relieve symptoms and maintain the patient’s quality of life.